![]() The randomised arm of the haemodynamic-GUIDEed management of Heart Failure (GUIDE-HF) trial was a multicentre, single-blind study at 118 centres in the USA and Canada. This trial was designed to evaluate whether haemodynamic-guided management using remote pulmonary artery pressure monitoring could reduce heart failure events and mortality in patients with heart failure across the spectrum of symptom severity (NYHA funational class II-IV), including those with elevated natriuretic peptides but without a recent heart failure hospitalisation. ![]() It is unclear if these benefits extend to patients with mild (NYHA functional class II) or severe (NYHA functional class IV) symptoms of heart failure or to patients with elevated natriuretic peptides without a recent heart failure hospitalisation. Previous studies have suggested that haemodynamic-guided management using an implantable pulmonary artery pressure monitor reduces heart failure hospitalisations in patients with moderately symptomatic (New York Heart Association functional class III) chronic heart failure and a hospitalisation in the past year, irrespective of ejection fraction. 15 Advocate Heart Institute, Naperville, IL, USA.13 Providence Hospital, Southfield, MI, USA.12 Louisiana State University School of Medicine, New Orleans, LA, USA.11 University of Kansas School of Medicine, Kansas City, KS, USA.10 East Carolina University, Greenville, NC, USA.9 Catawba Valley Health System, Conover, NC, USA.8 University of California San Diego, La Jolla, CA, USA.7 John Ochsner Heart and Vascular Institute, Ochsner Medical Center, New Orleans, LA, USA.6 Integris Baptist Medical Center, Oklahoma City, OK, USA.5 Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |